CClinicalTrials.gg
Status unknownNCT03425318CNAP in ARDSUpdated Apr 13, 2023

Continuous Negative Abdominal Pressure in ARDS (CNAP in ARDS)

An interventional study of CNAP in Acute Respiratory Distress Syndrome, sponsored by The Hospital for Sick Children. Status unknown at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim is to test a device for applying continuous negative abdominal pressure in patients with ARDS

Read the detailed description

Adult respiratory distress syndrome (ARDS) is a serious pulmonary disease affecting adults and children. It has a high mortality and there is no specific therapy. The mortality is high (approx. 40% in severe cases) and this has not changed in the last 20 years.

Mechanical ventilation is the mainstay of management, and this assists the patient by increasing oxygenation and removal of carbon dioxide. Despite optimizing tidal volume, driving pressure and positive end-expiratory pressure (PEEP), patients with ARDS develop large areas of atelectasis and poor oxygenation. There are few additional ventilator approaches that have proven to be useful in preventing this type of injury.

A major aim of ventilator support is recruitment of atelectatic (i.e. de-airated) lung, but while this is supported by excellent rational and laboratory data, the conventional clinical approaches have not been associated with a demonstrable improvement in patient outcome. Most atelectasis in ARDS occurs in the dorsal (dependant, lower-most) lung regions, and these are near the diaphragm.

The main ways to recruit lung are to increase the airway distending pressure (but this over-expands and damages the already-aerated lung regions); or, to turn the patient into the prone position (but clinicians are reluctant to utilize this approach - despite evidence that it may increase survival).

Continuous Negative Abdominal Pressure (CNAP) aims to selectively recruit basal atelectatic areas of lung, while enabling the patient to remain in the supine (usual) position.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients ≧ 18 years old
  2. Patients with moderate to severe ARDS as per the Berlin definition (PaO2/FiO2 ≤200mmHg)
  3. Patients with absence of any significant cardiopulmonary disease

Exclusion criteria

Exclusion Criteria:

  1. Contraindication to CNAP

    a. open abdominal wounds or drainage tubes; b. Acute brain Injury with intracranial pressure >30 mm Hg or cerebral perfusion pressure \<60 mmHg; c. Decompensated heart insufficiency or acute coronary syndrome; d. Major hemodynamic instability: Mean arterial pressure lower than 60 mm Hg despite adequate fluid resuscitation and two vasopressors or increase of vasopressor dose by 30% in the next 6 hours; f. Unstable spine, femur, or pelvic fractures; g. Pregnancy; h. Pneumothorax;

  2. Contraindication to EIT electrode placement: Burns, chest wall bandaging limiting electrode placement
  3. Severe liver insufficiency (Child-Pugh score > 7) or fulminant hepatic failure
  4. Major respiratory acidosis or PaCO2 > 60 mmHg
  5. Severe COPD (according to the GOLD criteria defined as severe = FEV1: 30-50% or very severe = FEV1 \< 30%)
  6. Clinical judgement of the attending physician
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Single arm

    Patients with ARDS will be placed inside of a Continuous Negative Abdominal Pressure Device. Negative pressure will be applied to the abdomen as an adjunct to positive pressure ventilation

    Device: CNAP

Interventions

  • DeviceCNAP

    Application of CNAP in patients with ARDS

05

What researchers measure

Primary outcomes

  1. Hypotension (SAFETY)

    Reduction in mean arterial pressure to less than 60 mmHg or by 15%

    Time frame: 30 min

  2. Oxygen Saturation (SAFETY

    Reduction in oxygen saturation (SpO2) by 5% or more

    Time frame: 30 min

  3. Oxygenation (SAFETY)

    Reduction in P-to-F ratio (PaO2/FiO2) by \>20%

    Time frame: 30 min

Secondary outcomes

  1. Oxygenation (EFFICACY)

    Increase in PaO2/FiO2 by \>20%

    Time frame: 30 min

06

Study locations

1 of 1 sites recruiting
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 5, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — undecided

08

Registry details

Key details

Study ID
NCT03425318
Lead sponsor
The Hospital for Sick Children
Collaborators
Unity Health Toronto
Responsible party
Felix Ratjen (Division Head Respiratory Medicine, The Hospital for Sick Children) — Principal investigator
First posted
Feb 7, 2018
Start date
Jan 4, 2019
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Apr 13, 2023

Study contacts

Doreen Engelberts
Contact
doreen.engelberts@sickkids.ca
416 813 8891
Laurent Brochard, MD
Contact
Laurent.Brochard@unityhealth.to
416 864 5686
Laurent Brochard, MD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion